AIM Vaccine Rises on its First Day on HKEx Main Board

2022-10-12 Source:Aimbio
AIM Vaccine Co., Ltd. (06660.HK) closed at HK$ 16.66, up 3.09%, on October 6, its first day on HKEx Main Board. 

With the mission of “developing and manufacturing top quality vaccines to safeguard the health of the world,” AIM Vaccine has established its position as a leading enterprise in the domestic vaccine industry after years of development. Its listing on HKEx has been well received by investors for its full technology platform, full industrial chain layout, rich product pipeline, efficient R&D and technology transformation ability, solid industrial strength and experienced commercialization competence. 

According to CIC (China Insights Consultancy), AIM Vaccine is the second largest (the largest privately owned) vaccine group in China (excluding COVID-19 vaccines) in terms of lot release in 2021, and the only Chinese vaccine enterprise with all five proven human vaccine platform technologies globally. Its 8 commercialized products cover 6 vaccine-preventable diseases, and 22 vaccines for 13 diseases are under development, with 5 of which in the clinical stage. Its innovative products, including mRNA COVID-19 vaccine and 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13), have entered Phase III clinical trials. 

At the listing ceremony, Zhou Yan, founder, Chairman and CEO, members of the Board of Directors, representatives of the management of AIM Vaccine, as well as government and investment institution representatives and other guests, together sounded the gong for its listing in HKEx. Representatives from all sectors of the society, especially the industry and investment institutions, expressed their sincere wishes to and firm confidence in the development of AIM Vaccine after the listing.

Looking forward, AIM Vaccine will continue to remain true to its original aspiration, develop blockbuster products, engage in the building of big production and omni capacities, develop itself from a follower of innovation to a leader of innovation, build its own “hard core technology”, establish the Chinese vaccine brand, and contribute to the realization of the Healthy China strategy.